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Michael Roth,1 Julie Krystal,2 Deepa Manwani,1 Catherine Driscoll,1 Rosanna Ricafort1We describe adolescents’ and parents’ interest in hematopoietic stem cell transplant (HSCT) as a cure for
sickle cell disease (SCD) and factors associated with increased interest. We administered a 40 question sur-
vey to assess the interest in HSCT in parents and adolescents with HBSS or HBSb0 thalassemia. The survey
tool assessed factors that may influence interest in HSCT including demographic data, disease severity, views
on prognosis, and health-related quality of life (HRQOL). All participants were given a handout on the risks
and benefits of an HSCT before completing the survey. One hundred twenty-nine parents and 59 adolescents
completed the survey. Forty-five percent of parents (54 of 119) would likely have their child undergo HSCT,
and 35% of adolescents (19 of 55) would likely undergo HSCT if it was recommended by their hematologist.
Parents of adolescents, as well as adolescent patients with better HRQOL, were more interested in HSCT.
Prior exchange transfusion was associated with increased interest in HSCT (62% [23 of 37] versus 38%
[29 of 76]; P 5 .02). The majority of parents believe their child’s SCD will get better (66%; [80 of 122]),
will not likely prevent their child from achieving life goals (83%; [100 of 121]), and will not shorten their child’s
lifespan (86%; [102 of 119]). There is strong parent and adolescent interest in HSCTas a cure for SCD. It is
concerning that few parents and adolescents believe SCD will negatively impact their prognosis. Education
on the potential long-term sequelae of SCD is needed when considering the role for HSCT.
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Sickle cell disease (SCD) is the most common in-
herited blood disorder in the United States affecting
more than 70,000 children and adults. Many patients
with SCD have significant sequelae from their disease
including frequent pain crises, respiratory illnesses,
and strokes [1,2]. In addition, patients with sickle cell
anemia have shortened lifespans, with an average life
expectancy between the fifth and sixth decade of life
[3]. SCD often leads to chronic, debilitating condi-
tions, with over 30% of adults on disability, and over
50%unemployed [4]. Studies have also shown children
with SCD have a significantly poorer health-related
quality of life (HRQOL) compared with children with-
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(HSCT) is the only known cure for SCD [8-12].
Given the risk of morbidity and mortality during and
after the transplantation, currently, transplantations
are only being offered for patients with the highest-
risk disease, including children with a history of
a stroke, multiple episodes of acute chest syndrome,
or recurrent vaso-occlusive crises [8-12]. Parents,
patients, and physicians must weigh the risks of
graft rejection, infection during transplantation,
immunosuppression, graft-versus-host disease
(GVHD), and death against the potential benefits of
a life without SCD when deciding whether to undergo
transplantation. Prior studies have shown that a sub-
stantial proportion of adult patients and parents of chil-
dren with SCD are willing to accept a certain amount
of risk in the hopes of curing their disease and living
a normal life [13,14]. Despite interest in stem cell
transplant, relatively few eligible patients are treated
with an HSCT [15]. Interestingly, prior studies did
not show a correlation between disease severity and in-
terest in HSCT, and adult patients’ interest in HSCT
often did not match physicians’ recommendations
[13,14].
To our knowledge, no studies to date have exam-
ined the willingness to proceed with transplantation
from the perspective of the pediatric patient, and it is1709
1710 Biol Blood Marrow Transplant 18:1709-1715, 2012M. Roth et al.currently unclear what factors are associated
with patient and parent interest in HSCT [13,14].
Analysis of these factors in the modern era of HSCT
will help to address the clinical and ethical dilemmas
facing physicians posed with offering this poten-
tially curative therapy to their patients. This study
examined the impact of factors such as HRQOL,
perceptions of disease severity, views on prognosis,
and patient and parental interest in undergoing
transplantation as a cure for SCD.MATERIALS AND METHODS
Population
Pediatric patients with SCD (HBSS and HBSb0
thalassemia [HBSbthal]) ages 5 to 21 years were con-
sidered eligible for this study. Parents of children
ages 2 to 21 years with SCD (HBSS or HBSbthal0)
were also eligible for this study. Exclusion criteria
included patients with HBSC andHBSbthal1, as these
patient populations often have less-severe disease.
Additional exclusion criteria were patients and parents
who did not speak English or Spanish.
Outcome Measures
We hypothesized that parents who perceived their
child’s HRQOL as poor are more likely to be inter-
ested in pursuing an HSCT for their child compared
with parents who perceived their child’s HRQOL as
good. The main outcome was the proportion of par-
ents of children with ‘‘low HRQOL’’ interested in
HSCT versus the proportion of parents of children
with ‘‘standard HRQOL’’ interested in pursuing an
HSCT. Secondary endpoints were the proportion of
adolescents with SCD interested in undergoing
HSCT, as well as the proportion of adolescents with
SCD with ‘‘low HRQOL’’ interested in HSCT versus
the proportion of adolescents with SCD with ‘‘stan-
dard HRQOL’’ interested in HSCT. Additional sec-
ondary endpoints included the association between
adolescent and parent views on prognosis, disease se-
verity, and demographic data with interest in HSCT.
Survey Instruments
A task force composed of physicians from pediatric
hematology, pediatric stem cell transplant, and pediat-
ric psychology (n 5 6) designed a 35-question survey
to assess the interest in HSCT as a cure for SCD in
parents and adolescents with HBSS or HBSbthal0
(Supplemental Figure 1). The survey tool assessed
factors that may influence interest in HSCT including
demographic data, disease severity, and views on prog-
nosis. The 35-question survey instrument was based
on the survey tools used in prior studies, which in-
cluded factors that may impact sickle cell patients’ in-
terest in HSCT, as well as impact their HRQOL[14,16]. Similar to these tools, clinical variables were
determined by patient/parent self-reports. Based on
an interim analysis, 5 additional questions were sub-
mitted as an amendment to assess patient and parent
hypothetical views on HSCT given varying degrees
of life expectancy, ranging from 30 years to 70 years.
In addition, HRQOL was assessed on the pediatric
quality of life inventory version 4.0 (PedsQL4.0).
The parent and patient surveys had a Flesch-Kincaid
grade level of #5.4 and a Flesch Reading Ease .76.
The PedsQL4.0 is a 23-question HRQOL assess-
ment tool that has been validated in the pediatric pop-
ulation in both healthy children and children with
chronic disease [17-20]. The inventory assesses
childrens’ and adolescents’ physical, emotional,
social, and school functions over the prior 4 weeks.
The PedsQL4.0 has been specifically validated in
children and adolescents with sickle cell anemia
[16,21]. The largest study included over 1700
children with SCD and their parents from various
institutions [16]. Internal consistency was stronger in
parent reports than in child reports (Cronbach’s
alpha 5 0.79-0.95 and 0.69-0.88, respectively). Mod-
erate correlation was seen between child and parent
reports with the lowest correlation existing in the child
age 5 to 7 group and the highest correlation in the
adolescent group (Pearson’s coefficient 5 0.36-0.39
and 0.48-0.55, respectively). A self-report inventory
is available for children over age 4, whereas a parent
proxy inventory is available for all children age 2 and
older [17,21]. Four scales comprise the PedsQL4.0:
Physical functioning, Emotional functioning, Social
functioning, and School functioning. The inventory
uses a 5-point Likert scale that is transformed into
a scale from 0 to 100 with scores of 100 representing
the highest quality of life. Missing items were
accounted for based on the developer’s administration
guidelines [22].
Study Protocol
Patients were recruited consecutively in the pedi-
atric hematology outpatient clinics as well as the
inpatient floor. All eligible patients were approached
and offered participation in the study. The study was
approved by the institutional review board at Monte-
fiore Medical Center. Written informed consent was
waived as the consent document would have been
the only link between patient identifiers and survey
responses. Verbal consent was obtained. All partici-
pants were given a handout on the risks and benefits
of anHSCT before completing the survey. Themajor
risks and benefits highlighted on the handout
included: 5% to 10% risk of death, 8% to 12% risk
of graft rejection, less than 10% risk of GVHD, and
an 85% chance of cure (Supplemental Figure 2)
[8,11,23,24]. Patients age 4 to 21 years completed
the age-appropriate PedsQL4.0. Patients age 13 to
Table 1. Demographics
Parent
Participants
(n 5 129) % (n)
Adolescent
Participants
(n 5 59) % (n) P Value
Child age (years)
2-4 19 (26)
5-7 21 (26)
8-12 37 (46)
13-21 24 (31)
Sex, child
Boys 58 (75) 58 (34) 1.000
Girls 42 (54) 42 (25)
Race/ethnicity
African American 77 (97) 73 (37) .701
Hispanic 20 (25) 24 (12) .683
Education
#Middle school 11 (13)
High school 51 (32)
$College 38 (44)
Frequent pain crises* 54 (69) 59 (34) .634
Prior acute chest syndrome 58 (74) 60 (35) .872
Prior simple transfusion 77 (98) 95 (55) .003
Prior exchange transfusion 31 (39) 34 (20) .735
Prior stroke 10 (13) 19 (11) .259
Current hydroxyurea use 53 (66) 61 (36) .202
*>2 pain crises/year.
Table 2. Interest in Transplantation by Age
Age of Child, years Likely Undergo HSCT % (n)
Parent views All 45 (54)
2-4 38 (9)
5-7 63 (15)
8-12 40 (18)
13-21 48 (12)
Adolescent views 13-21 35 (19)
P value* .191
HSCT indicates hematopoietic stem cell transplantation.
*P value represents parent views (ALL) versus adolescent views.
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Parents of children of all ages completed both the
age-appropriate PedsQL4.0, as well as the developed
survey tool.
Statistics
We estimated a minimal sample size of 43 parents
in each group to obtain an 80% power (type I error
0.05 with a 2-tailed test) considering the smallest
difference in the proportion of parents of children
with ‘‘standard HRQOL’’ versus parents of children
with ‘‘low HRQOL’’ interested in transplantation to
be 25% (10% to 35%). Standard descriptive statistics
were computed for all variables. The Fisher exact test
was used to evaluate bivariate associations between
categorical variables. For missing data points on
the PedsQL4.0, mean-substitution was used for
items within each subscale, as long as 50% of the
items were completed. Participants who responded
they definitely or probably would undergo HSCT
if recommended by their hematologist were catego-
rized as ‘‘likely would undergo HSCT,’’ whereas par-
ticipants who responded they would maybe,
probably not, or definitely would not undergo
HSCT were categorized as ‘‘less likely would un-
dergo HSCT.’’ Means were calculated for all subcat-
egories on the PedsQL4.0. Scores below the mean
were grouped into the category ‘‘low HRQOL,’’
and scores greater than or equal to the mean were
grouped into the category ‘‘standard HRQOL.’’
The level of significance for all statistical tests was
2-sided, P \ .05. Statistical analysis was performed
using SPSS, version 18.0 for Windows (SPSS, Inc.,
Chicago, IL).RESULTS
Demographics
One hundred twenty-nine parents and 59 adoles-
cents age 13 to 21 years completed the survey. One
parent refused participation in the study and no ado-
lescents refused participation. Ten parents did not
respond to the questions regarding interest in trans-
plantation. Four patients had both of their parents
complete the survey, resulting in 125 total unique
patients represented on the parent surveys. Twenty-
one adolescents had matched parent responses as
many of the older adolescents with SCD do not
come to the clinic or the hospital floor accompanied
by a parent. Eighty-eight percent of parent respon-
dents were the patient’s mother. Children of all ages
were well represented in the study, and patients had
varied disease severity. Respondent demographic
data is shown in Table 1.
Interest in HSCTas a Cure for Sickle Cell
Anemia
Forty-six percent of parents and 35% of adoles-
cents would likely accept HSCT if it were recommen-
ded by their hematologist. Parent interest inHSCTdid
not vary significantly by child age (P5 .430) (Table 2).
Parentswith prior knowledge onHSCTwere notmore
likely to be interested in HSCT than parents without
prior knowledge (46.7% versus 40.5%; P 5 .518).
There was no significant difference in interest in
transplantation in parents of children who were inpa-
tients versus outpatients (55% versus 45%; P 5 .79)
or adolescents who were inpatients versus outpatients
(36% versus 34%; P 5 .915). Seventy-six percent of
parents and 61% of adolescents who would not likely
undergo transplantation responded that they would
like more information on HSCT.
Quality of Life in anUrban Sickle Cell Population
Quality of life of all participants was measured on
the PedsQL4.0. Adolescents had poorer overall
HRQOL as measured by mean total score (59.7%
versus 69.3%; P 5 .017) compared with patients
younger than age 13 years. Specifically, adolescents
Table 3. Parent and Patient Report Mean Scores PedsQL4.0
PedsQL Category
Parent Report
Age
2-4
Age
5-7
Age
8-12
Age
13-21 ALL
*P
value
**P
value
Physical fx 76.0% 66.5% 67.2% 57.6% 66.3% .035 .013
Emotional fx 70.4% 65.9% 70.2% 65.9% 68.8% .849 .517
Social fx 86.3% 72.8% 71.7% 70.2% 74.2% .041 .337
School fx 64.2% 63.0% 60.1% 48.0% 59.2% .035 .004
Total emotional fx 75.8% 67.6% 67.3% 61.2% 67.8% .112 .056
Total score 75.9% 67.1% 67.2% 59.7% 67.2% .022 .017
PedsQL Category
Patient Report
Age 5-7 Age 8-12 Age 13-21 ALL
Physical fx 71.7% 68.4% 64.1% 67.8%
Emotional fx 57.1% 66.6% 71.2% 65.7%
Social fx 68.6% 74.3% 78.4% 74.0%
School fx 61.9% 60.2% 57.0% 60.4%
Total emotional fx 61.8% 67.2% 68.9% 66.6%
Total score 65.4% 67.6% 67.2% 67.0%
PedsQL4.0 indicates pediatric quality of life inventory version 4.0; fx,
function.
*P value represents 1-way analysis of variance assessing difference in
PedsQL mean scores by age.
**P value is t test between age <13 versus age $13.
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70.0%; P5 .013) and poorer mean school functioning
(48.0% versus 62.2%; P5 .004). Mean values for each
quality of life subcategory are shown in Table 3. In ad-
dition to age, markers of disease severity were also as-
sociated with poorer quality of life. Patients with more
than 2 pain crises per year were more likely to have
poorer physical (57.8% versus 25.0%; P\ .001), emo-
tional (57.8% versus 32.1%; P 5 .005), social (58.5%
versus 32.1%; P 5 .004), and total functioning
(66.2% versus 23.2%; P \ .001). Patients who had
a prior stroke had poorer school functioning (76.9%
versus 39.8%; P 5 .011), and patients on hydroxyurea
had poorer physical (53.3% versus 29.3%; P 5 .008)
and total functioning (54.1% versus 36.2%; P5 .050).
Beliefs on Prognosis
Few parents (14%) believe that SCD will shorten
their child’s lifespan and only 7% of parents believe
their child’s life will be cut short by more than 10 years
(Table 4). Overall, adolescents were more likely toTable 4. Parent and Patient Views on Prognosis
Age of Child, years SCDWill Get Better % (n)
Parent views All 65 (78)
2-4 50 (12)
5-7 64 (16)
8-12 66 (29)
13-21 78 (21)
Adolescent views 13-21 51 (29)
P value* .071
SCD indicates sickle cell disease.
*P value represents parent views (ALL) versus adolescent views.believe SCD would shorten their lifespans compared
with parents’ views (32% versus 14%; P 5 .008).
Two-thirds of all parents believe their child’s SCD
will get better when they get older, and most parents
(82%) and adolescents (74%) do not believe SCD
will prevent them from achieving life goals (Table 4).
Increased disease severity and poorer HRQOL
were associated with parent and patient beliefs that
SCDwould negatively impact their prognosis, longev-
ity, and/or ability to achieve life goals (Supplemental
Tables 1 and 2). Prior exchange transfusion, stroke,
poor emotional functioning, and poor school func-
tioning were each associated with patients’ beliefs
that SCD will prevent them from achieving life goals.
In addition, adolescents prescribed hydroxyurea and
adolescents with poor physical functioning or poor
emotional functioning were more likely to believe
that SCD will shorten their lifespans.
Comprehension of the Risks and Benefits of
HSCT
Parent and patient understanding of the risks and
benefits of HSCT was assessed on the survey tool.
The majority of respondents understood the risks and
benefits of HSCT. Eighty percent of parents and
81% of adolescents correctly answered that during
a sibling-matched HSCT, a sibling without sickle cell
donates his or her stem cells to a child with sickle cell.
Seventy-six percent of parents and 71% of adolescents
correctly identified the cure rate associatedwithHSCT
with only 4% of parents and 2% of adolescents overes-
timating the cure rate. Eighty-one percent of parents
and 78% of adolescents correctly identified the mor-
tality rate during HSCT with only 6% of parents and
0% of adolescents underestimating the risk of death.
HRQOL and Interest in Transplantation
Overall, parents of children with ‘‘low HRQOL’’
were not more likely to be interested in HSCT com-
pared with parents of children with ‘‘standard
HRQOL.’’ Surprisingly, the impact of HRQOL on
parent interest in HSCT varied significantly by age.
In the pre-adolescent age group, poorer HRQOL
was associated with positive interest in undergoingSCDWill NOT Likely Prevent
Life Goals % (n)
SCDWill NOT Likely Shorten
Lifespan % (n)
82 (99) 86 (101)
92 (22) 87 (20)
88 (21) 72 (18)
75 (34) 91 (39)
79 (22) 89 (24)
74 (42) 68 (38)
.169 .008
Figure 1. Parent and adolescent interest in HSCT is associated with perception of HRQOL. (A) Parents’ of children ages 8-12 interest in HSCTwith
‘‘standard’’ HRQOL (high fx) versus ‘‘low’’ HRQOL (low fx). *P\.05, **P\.01. (B) Parents’ of children ages 13-21 interest in HSCTwith ‘‘standard’’
HRQOL (high fx) versus ‘‘low’’ HRQOL (low fx). (C) Adolescents’ ages 13-21 interest in HSCTwith ‘‘standard’’ HRQOL (high fx) versus ‘‘low’’ HRQOL
(low fx).
Table 5. Factors Associated with Increased Parental Interest
in HSCT
Likely Undergo
Transplantation % P Value
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verse was true: parents were more willing to accept
HSCT for their adolescents with a ‘‘standard’’ versus
‘‘low’’ HRQOL. As a whole, adolescents’ willingness
to proceed with HSCT mirrored the parental views
based on HRQOL (Figure 1).
Patient-Related Factors Associated with
Increased Interest in Transplantation
Interest in HSCT was associated with increased
disease severity and the belief that disease-related
prognosis is worse. Prior exchange transfusion was
the only disease-related factor associated with in-
creased parent interest in HSCT (62% versus 38%;
P 5 .016) (Table 5). Parents with more than 1 child
with SCD, as well as parents of boys, were more likely
to be interested in HSCT; however, these did not
achieve statistical significance. Additionally, parents
who missed more than 1 week of work each year sec-
ondary to their child’s SCD were more likely to be
interested in HSCT (55.2% versus 30.4%; P 5 .012).
Parents of all children older than 4 years who be-
lieved their child’s life would be shortened by SCD
were more interested in transplantation (79% versus
40%; P5 .008) (Table 5). Given an interim data anal-
ysis revealed that very few parents believed their child’s
life expectancy would be reduced by SCD, we submit-
ted an amendment to ascertain patient and parent hy-
pothetical views on HSCT with varying degrees of life
expectancy, with lifespans ranging from 30 years to
70 years. Parent and patient interest in HSCT in-
creased with lower predicted life expectancy (Figure 2).Prior exchange transfusion Yes 62.2 (23/37) .016
No 38.2 (29/76)
No. of children with SCD >1 60.7 (17/28) .082
1 40.5 (36/89)
Sex of child with SCD Boy 52.2 (36/69) .080
Girl 36.0 (18/50)
Work missed per year >1 week 55.2 (37/67) .012
<1 week 30.4 (14/46)
Belief SCD will shorten life* Yes 78.6 (11/14) .008
No 40.3 (31/77)
HSCT indicates hematopoietic stem cell transplantation; SCD, sickle cell
disease.
*Views of parents of children older than age 4.DISCUSSION
In this study, we report parent and adolescent in-
terest in HSCT as a cure for SCD and the factors asso-
ciated with increased parent and patient interest. To
our knowledge, this is the first study that directly as-
sessed adolescents’ interest in undergoing a stem cell
transplant for a chronic illness. Our study shows that
more than one-third of parents and adolescents arewilling to accept the current risk of morbidity and
mortality of a matched-sibling HSCT in the hopes
of curing their SCD.
Our study demonstrates that parent interest in
HSCT as a cure for SCD is associated with disease
severity. The finding that a history of an exchange
transfusion is associated with increased parent interest
inHSCT demonstrates for the first time that increased
perceived disease severity is related to parent interest
in HSCT. Two prior studies by Kodish et al. [13]
and van Besien et al. [14] did not find disease-related
factors associated with parent or patient interest in
HSCT; however, these studies did not report on ex-
change transfusions as a variable. In addition, to our
knowledge, our study is the first to report that parent
views on prognosis and patientHRQOL are associated
with interest in HSCT. Unexpectedly, the impact of
HRQOL on parent interest in HSCT varied by age,
and parents of adolescents with SCDwith better as op-
posed to poorerHRQOLweremore interested in pur-
suing an HSCT. This may be secondary to patient and
parent difficulty coping with the disease and a sense of
hopelessness as time goes by. Prior studies have shown
adolescents with SCD have more behavioral problems
than younger children, and many patients report a
feeling of hopelessness [25,26]. Further studies are
Figure 2. Parent and adolescent hypothetical views on HSCT given
varying degrees of life expectancy. Parents and adolescents were asked
about their interest in undergoing HSCT if their life spanwithout a trans-
plant would be 70, 60, 50, 40, or 30 years.
1714 Biol Blood Marrow Transplant 18:1709-1715, 2012M. Roth et al.needed to better understand the impact ofHRQOLon
adolescents’ and parents’ acceptance of disease and
ability to cope with their illness.
The majority of parents and patients do not be-
lieve SCD will likely prevent them from achieving
life goals, and they do not believe SCD will cut their
lives short. These views are not consistent with the
literature documenting the natural course of disease
in large populations of patients with SCD. Survival
in childhood and adolescence has improved with the
use of prophylactic antibiotics and vaccinations; how-
ever, mortality in early adulthood still remains high
[27-29]. Although the impact of hydroxyurea
therapy on survival is not yet clear, studies over the
past 20 years have shown the median age of death
for patients with homozygous HBSS is in the 5th to
6th decade of life [3,30,31]. The current life
expectancy in the United States is 78 years, which
means, on average, SCD will cut patients’ lives short
by at least 20 years [32]. It is concerning that only
14% of parents believe that SCD will cut their child’s
life short by as little as 5 years.
The HRQOL of children with SCD is poor com-
pared to the general pediatric population [21]. Our
parent proxy and patient scores on the PedsQL4.0
were consistent with Dampier’s study of HRQOL of
over 1700 children with SCD and confirms the finding
of poor functioning in all areas of HRQOL [16]. In
addition, we found that HRQOL in children with
SCD worsens as patients grow into adolescence.
Unfortunately, HRQOL does not improve as patients
enter adulthood, and a recent study showed adult
patients with SCD have a significantly poorer quality
of life compared to patients with other chronic dis-
eases, including cystic fibrosis [33]. In addition, adults
with SCD have difficulty achieving in the workforce as
few patients with HBSS complete college (\15%), few
have stable employment (20%), and the majority
(.70%) earn less than $10,000 per year [4,34].These factors should be considered when discussing
disease-modifying treatment options in childhood.
Educating patients on their illness is vital to pro-
viding patients the knowledge to be able to make
informed decisions regarding treatment options.
Unfortunately, the accurate communication of disease
outcomes in SCD is difficult given the large heteroge-
neity of disease severity seen in patients. Studies have
tried to identify risk factors early in life that could pre-
dict outcomes in patients with SCD [35]. In 2000,
Miller et al. [36] showed factors such as low hemoglo-
bin, leukocytosis, and episodes of dactylitis correlated
with increased adverse outcomes in childhood; how-
ever, the positive predictive value of each of these
markers was less than 50%. Subsequently, Quinn
et al. [37] demonstrated in a cohort of 168 patients
that this model was no better at predicting adverse out-
comes than random prediction. Our study findings —
that parents who believe their child’s life will be cut
short by SCD are more interested in undergoing
HSCT— stress the importance of being able to better
predict disease outcomes early in life.
This study has a few limitations. The study partic-
ipants are all from a single institution located in a very
poor, urban community andmay not be fully represen-
tative of all families with SCD in the United States.
The participants were all recruited in the clinic or on
the hospital floor, and thus our population may over-
represent patients with more severe disease as they
are more likely to be admitted and to visit the outpa-
tient clinic. Patients with recent acute clinical events
may have been more likely to report a poorer HRQOL
than their baselines. Additionally, parent and patient
interest in HSCT was hypothetical, and it is unclear
whether the participants would go forward with trans-
plantation if faced with this decision. Given the nature
of the study, our ability to include all of the short-term
and long-term side effects of HSCT was limited. Our
study focused on the risk of death, graft rejection, and
GVHD, as was the focus in the 2 prior studies assessing
parent and adult patient interest in HSCT for SCD
[13,14]. Finally, parents and adolescents were asked
their interest in undergoing HSCT after reading
a brief handout, whereas in practice, families who are
preparing for HSCT have numerous meetings and
discussions with the sickle cell and transplantation
medical team to comprehensively discuss the risks
and benefits of HSCT.
A significant proportion of adolescents with SCD
and their parents are interested in HSCT, and they
are willing to accept the risk of acute mortality in the
hopes of achieving a cure. A number of factors are as-
sociated with increased interest in transplantation, in-
cluding disease severity, HRQOL, and views on
prognosis. It is concerning that many families may
not have realistic expectations regarding the natural
course of SCD. SCD, like stem cell transplants, have
Biol Blood Marrow Transplant 18:1709-1715, 2012 1715SCT for Children with Sickle Cell Anemiamany serious risks; however, many of these risks sig-
nificantly increase later in life. It is our duty to educate
patients and families to ensure they have the knowl-
edge to be able to make informed decisions on treat-
ment options for their SCD.ACKNOWLEDGMENTS
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